Answers are grounded in this paper and cite their sources.
Restricting new uses of per- and polyfluoroalkyl substances (PFAS) cannot immediately stop release from products and technical systems already in use. This delay was quantified for the European Economic Area with a cohort-resolved substance flow model in which market inflow is a prescribed input and release and stocks are outcomes. The model follows PFAS placed on the market from 1950 to 2070 through use, waste treatment and five environmental compartments under a comprehensive restriction, a partial restriction with derogations and no further restriction. Cumulative release in 2027--2070 was 4200~kt [3200--5700, 5th--95th percentile over sampled market inputs] without further restriction. The partial and comprehensive restrictions avoided 64\% and 83\% of it, but the comprehensive restriction needed a decade to avoid half. Mass placed on the market before 2027 released at least 700~kt by 2070 in every scenario and supplied almost all release under the comprehensive restriction. The derogations retained about a quarter of the release the comprehensive restriction avoided, nine tenths of it fluorinated gases, because retained uses release a larger fraction of their inflow than the uses stopped. Environmental stocks responded more slowly: under the comprehensive restriction the summed stock fell to about half of its 2027 value by 2070 (half to three quarters across the residence-time variants), while soil, groundwater and sediment kept accumulating in every parameterisation. The measured effect of a restriction therefore depends on the evaluation window and on the compartment considered, and tonnage alone does not indicate the release a derogation retains.
No takes yet. Share an insight, caveat, or question.
Falzberger et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: